Pharmaceutical Behemoth Bristol-Myers Squibb and Cancer’s Biotech Celgene Agree to Stock and Cash Deal
Bristol-Myers (BMY) and Celgene (CELG) have agreed to a $74 billion deal that heralds a new era in cancer research, by merging the two companies who’ve made a lot of investments in cancer immunotherapy in 2018.
- Celgene (CELG) is trading (+32%) in the pre-market session, near $88.35/share, breaking out of its descending wedge this morning.
Bristol-Myers (BMY) Celegene (CELG) Deal
Bristol-Myers has agreed to pay Celgene shareholders one BMY share and $50 cash for each Celgene share they own. Celgene investors will also receive rights to future shares that will pay out if the combined company meets certain regulatory milestones.
“As a combined entity, we will enhance our leadership positions across our portfolio, including in cancer and immunology and inflammation,” Bristol-Myers CEO.
Celgene was a lackluster trade in 2018, reflecting big-ticket acquisitions of Juno Therapeutics and Impact Biosciences. Celgene’s stock is off 58% from its 2017 highs. The combined companies should create some competition for its blockbuster cancer treatment, Revlimid.
Bristol-Myers also faced persistent competition from companies like Merck in cancer immunotherapy. That said, Bristol-Myers drugs, Opdivo and Yervoy, show promise in harnessing the body’s immune system to treat cancer. An aging population welcomes these advances in cancer immunotherapy R&D.
We’ll sell our remaining position in CELG this morning and reassess a potential position in BMY or MRK after the dust settles.
Watch gaming stocks today: WYNN LVS PENN SGMS
Join us for our LIVESTREAM broadcast during market hours. Watch, listen and trade from 9:20 AM to 4:15 PM Monday through Friday.
Happy Trading,
Vinny
Disclaimer: Do your Own Research
Our content is intended to be used and must be used for informational purposes only. It is very important to do your own analysis before making any investment based on your own personal circumstances. You should take independent financial advice from a professional investment advisor in connection with, or independently research and verify, any information that you find on our Website and wish to rely upon, whether for the purpose of making an investment decision or otherwise. Trades and or positions listed and taken from the watchlist are my own and should not be considered “advise” to enter any particular position or asset.
Investment Warnings
We would like to draw your attention to the following important investment warnings. The value of shares and investments and the income derived from them can go down as well as up; Investors may not get back the amount they invested – losing one’s shirt is a real risk; past performance is not a guide to future performance.
Live Sessions
Live broadcasts are educational in their content. Proper risk management is considered on every trade or asset mentioned.
*** Stocks highlighted are for information purposes only and should not be considered as advice to purchase or to sell mentioned securities.
As always, the use of technical and fundamental analysis is encouraged in order to fine tune entry and exit points to average seasonal trends.
These mentions are stocks that we may or may not decide to trade as outlined in the watchlist. Always use a stop.